by Laura Turbay | Sep 23, 2024
Small-cap biotech stocks plundered after a 2021 wild-run, but investors are hopeful that interest rate cuts and positive test results in oncology and autoimmune treatments will be the right prescription for the biopharma market. That would be welcome news for...
by Mariam Kiparoidze | Nov 3, 2023
Photo credit:Wikimedia Commons Pfizer reported a loss in the third quarter as it tries to adapt to the faltering demand on its Covid-19 drug and vaccines. Pfizer reported a net loss of $2.38 billion last quarter, missing analyst expectations, the pharmaceutical giant...
by Mariam Kiparoidze | Sep 28, 2023
Even though Covid-19 cases and hospitalization numbers are up, they won’t be a shot in the arm for either Moderna or Pfizer stock. Pfizer (NYSE:PFE) closed at $32.69 per share, down by 36.2% year to date on September 22. Moderna (Nasdaq:MRNA) ended the week on a...
by Juliet Jeske | Oct 25, 2021
After 12 years of a physically and emotionally abusive marriage Tara decided she couldn’t take it anymore and moved out with her two small children. Less than a month later COVID-19 was declared a global pandemic and any hope she had for a swift divorce was...
